Lundbeck profits killed by patent loss; Meda CEO looking for acquisitions; FDA's Hamburg often at White House;

@FiercePharma: Cancer drugs from J&J, Roche, Celgene and more rival last big oncology wave. Story | Follow @FiercePharma

@TracyStaton: Popular at FiercePharmaMarketing: Payers fret about the next drug doomsday: Pricey PCSK9 cholesterol meds. More | Follow @TracyStaton

@EricPFierce: CEO says Teva will close at least 11 plants, 15% of its network, and 16 more are being evaluated. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Today, digital health contests like Bayer's. Tomorrow? Pharma needs digital disruption. More | Follow @CarlyHFierce

> Danish pharmaceutical company H. Lundbeck reported a 69% drop in first-quarter net profit as the patent in Europe expired for its dementia drug Ebixa. Report

> Juan Ramón Alaix, CEO of Pfizer ($PFE) animal health spinoff Zoetis, said that concerns over animal antibiotic use in Europe and U.S. will not keep sales of the drugs from growing worldwide. Story

> The CEO of Meda, which recently spurned a takeover offer by Mylan ($MYL), reported higher earnings for the Swedish drugmaker and said the company could make some acquisitions of its own. Story

> Cambridge, MA-based Momenta Pharmaceuticals ($MNTA) reported a net loss of $27.4 million, or 53 cents per share in the first quarter, compared to a net loss of $24.1 million, or 48 cents a share, in the year-ago quarter. Report

> A settlement has been reached in which the owners of the now-bankrupt New England Compounding Center, at the center of a meningitis outbreak that killed dozens, will contribute $50 million to a victims fund and insurers $25 million. Story

Medical Device News

@FierceMedDev: EndoGastric snags another $30M on the quest for reimbursement. Article | Follow @FierceMedDev

@VarunSaxena2: AdvaMedUpdate hires former Congressional, White House, HHS and CMSstaffer Riley Swinehart as VP of government affairs. | Follow @VarunSaxena2

@EmilyWFierce: Check out the latest FiercePharmaMarketing report to get the skinny on price hikes for 10 big brand drugs. Report | Follow @EmilyWFierce

@MichaelGFierce: Double-locked virus needs two enzyme 'keys' to release drugs. Story via FierceDrugDelivery | Follow @MichaelGFierce

> Alere recalls test strips after patient deaths. Article

> Boston Scientific shells out $65M for California gynecological surgery outfit. News

> Covidien sets sights on Turkey with latest training outpost. Piece

Biotech News

@FierceBiotech: Corcept tanks as depression drug comes up short in Phase III. More | Follow @FierceBiotech

@JohnCFierce: Who will buy into AstraZeneca's "$5B" high-risk Alzheimer's drug? Story | Follow @JohnCFierce

@DamianFierce: Pfizer has a whole website devoted to its AstraZeneca designs, PfizerUpdate.com, replete with an infographic. Site | Follow @DamianFierce

@EmilyMFierce: In Bhutan, there are only 8 ophthalmologists--about 90,000 patients for each eye doctor. Story | Follow @EmilyMFierce

> Cytomedix shutters R&D site after PhII failure. Item

> Roche and Exelixis tout PhI cancer combo with late-stage data on the way. Story

> Waiting for U.S. pols to block the Pfizer-AstraZeneca megamerger? Forget about it. More

Drug Delivery News

> Novel glaucoma drug delivery platform described at ARVO conference. More

> Boston Scientific launches Promus Premier drug-eluting stent in Japan. Item

> Icon begins pivotal late-stage trial of sustained-release postsurgery cataract treatment. Story

> Direct injection of drugs to back of eye shows potential. News

> Double-locked virus needs two enzyme 'keys' to release drugs. More

> Braeburn Pharmaceuticals to clinically test subdermal implant for treatment of opioid dependence. Article

Diagnostics News

> Ohio team touts promise of esophageal cancer biomarker and noninvasive screening test. News

> Accelerate Diagnostics' infectious disease tests draw $45M in new funding. More

> Biocept's new pharma industry cancer biomarker service sparks Nasdaq gains. Article

> Veracyte seals deal that opens Brazil market for its thyroid cancer Dx tech. Story

> France's Enterome pulls in $13.87M to pursue bowel inflammation biomarkers, companion Dx and Rx. More

Pharma Marketing News

> Drug ads miss the mark with patients who need treatment the most. News

> Keeping an M&A score? Here's the Big Pharma lineup, pre-megadeal. Story

> Add Apple's savvy to Big Pharma marketing, and what do you get? More

> 10 big brands keep pumping out big bucks, with a little help from price hikes. Report

> Cancer drugs from J&J, Roche, Celgene and more rival last big oncology wave. Story

> Payers already fretting about the next pharm-apocalypse: Pricey PCSK9 cholesterol meds. Article

And Finally... An analysis by Regulatory Focus found that in the last four years FDA Commissioner Margaret Hamburg made 61 trips to the White House to meet with officials, including the president, and Sally Howard, deputy commissioner of policy, planning and legislation, was there 43 times. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.